A new allosteric site in glycogen phosphorylase b as a target for drug interactions.Oikonomakos, N.G., Skamnaki, V.T., Tsitsanou, K.E., Gavalas, N.G., Johnson, L.N.
(2000) Structure 8: 575-584
- PubMed: 10873856
- DOI: 10.1016/s0969-2126(00)00144-1
- Primary Citation of Related Structures:
- PubMed Abstract:
- Allosteric Inhibition of Glycogen Phosphorylase a by the Potential Antidiabetic Drug 3-Isopropyl 4-(2-Chlorophenyl)-1,4-Dihydro-1-Ethyl-2-Methyl-Pyridine-3,5,6-Tricarboxylate
Oikonomakos, N.G., Tsitsanou, K.E., Zographos, S.E., Skamnaki, V.T., Goldmann, S., Bischoff, H.
(1999) Protein Sci 8: 1930
- The Structure of Glycogen Phosphorylase b with an Alkyldihydropyridine-Dicarboxylic Acid Compound, A Novel and Potent Inhibitor
Zographos, S.E., Oikonomakos, N.G., Tsitsanou, K.E., Leonidas, D.D., Chrysina, E.D., Skamnaki, V.T., Bischoff, H., Goldmann, S., Watson, K.A., Johnson, L.N.
(1997) Structure 5: 1413
In muscle and liver, glycogen concentrations are regulated by the coordinated activities of glycogen phosphorylase (GP) and glycogen synthase. GP exists in two forms: the dephosphorylated low-activity form GPb and the phosphorylated high-activity form GPa ...
In muscle and liver, glycogen concentrations are regulated by the coordinated activities of glycogen phosphorylase (GP) and glycogen synthase. GP exists in two forms: the dephosphorylated low-activity form GPb and the phosphorylated high-activity form GPa. In both forms, allosteric effectors can promote equilibrium between a less active T state and a more active R state. GP is a possible target for drugs that aim to prevent unwanted glycogen breakdown and to stimulate glycogen synthesis in non-insulin-dependent diabetes. As a result of a data bank search, 5-chloro-1H-indole-2-carboxylic acid (1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethy l)amide, CP320626, was identified as a potent inhibitor of human liver GP. Structural studies have been carried out in order to establish the mechanism of this unusual inhibitor.
Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, Athens, 11635, Greece. nikos@krokees. eie.gr.